&w=3840&q=100)
Dr Reddy's: Brokerage reports by JM Financial, Motilal Oswal as stock up 4%
Dr Reddy's stock price today Shares of Dr Reddy's Laboratories (DRL) surged 4 per cent to ₹ 1,203.60 on the BSE in Monday's intra-day trade amid heavy volumes after the company reported its March 2025 quarter earnings. The stock bucked the overall trend in the pharma stocks on Monday. Nifty Pharma index lost 2 per cent in intra-day deals on reports that US President Donald Trump is planning to lower prescription drug prices by making sure Americans don't pay more than people in the cheapest countries. MORE DETAILS HERE
At 10:45 am; DRL stock was trading 3.9 per cent higher at ₹ 1,201.25, as compared to 1 per cent rise in the BSE Healthcare index. The average trading volumes on the counter jumped over two-fold. A combined 3.24 million equity shares have changed hands on the NSE and BSE.
Dr Reddy's Q4 result
DRL posted a 22 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) for the fourth quarter of 2024-25 at ₹1,593.9 crore. The PAT beat enabled by higher Net Finance income and lower taxation due to reversal of tax provisions and the foreign currency translation reserve (FCTR) transfer being non-taxable.
Revenues for the period were up 20 per cent to ₹8,506 crore. The outperformance in topline is driven by significant jump in Europe because of Nicotine Replacement Therapy (NRT) acquisition, supported by contribution from generics portfolio. Earnings before interest, taxes, depreciation and amortisation (Ebitda) for the quarter was up 16.1 per cent at ₹2,050 crore. Ebitda margin dipped 80bp YoY to 24 per cent, due to lower gross margins and elevated SG&A.
Dr. Redd's Laboratories posted healthy growth in revenue across the segments, partly aided by the addition of acquired businesses. In addition, pharmaceutical services and active ingredients saw a healthy revival in FY25 performance vs. the muted show in FY23/FY24.
Management has guided for double-digit growth in FY26, with margins expected to remain similar to FY25 levels. Beyond FY26, Semaglutide and Biosimilars (including Abatacept) are expected to drive business performance.
Brokerage view: JM Financial Institutional Securities
Analysts at JM Financial expect the DRL's FY26 topline to grow at 23 per cent with Ebitda margins to remain at similar levels as seen in FY25. The brokerage firm has revised FY26E topline upwards by 8 per cent on account of expected Revlimid sales being greater than those earlier anticipated. Beyond FY26, Semaglutide and Biosimilars (including Abatacept) are expected to drive business performance, JM Financial said in a recent note. DRL plans to be present in all Semaglutide markets losing exclusivity in CY26, while Abatacept is scheduled for launch in CY27. Analysts believe the markets are underestimating the Semaglutide opportunity for Dr. Reddy's. While it may not fully replace Revlimid sales, it could substantially mitigate the earnings decline in FY27, the JM Financial note said.
Motilal Oswal Financial Services on Dr Reddy's Laboratories
After three years of strong 30 per cent earnings CAGR over FY21-24E, the company ended FY25 with a moderate 6 per cent earnings growth. DRL is implementing a plan to expand product offerings across markets and add/ build capacity to cater to the respective markets. Having said this, the intensified competitive pressures in the base portfolio would keep earnings growth in check.
About Dr. Reddy's
Dr. Reddy's Laboratories is a global pharmaceutical company headquartered in Hyderabad, India. The company offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. DRL's major markets include - USA, India, Russia & CIS countries, China, Brazil, and Europe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India.com
40 minutes ago
- India.com
Mukesh Ambani makes big move, sells stake worth Rs 77076598394 in this company due to..., company is...
Mukesh Ambani (File) In a significant move, billionaire Mukesh Ambani-led Reliance Industries Limited (RIL) has sold around 35 crore of its equity shares in Asian Paints at Rs 2,201 apiece for a total of approximately Rs 7,703.5 crore. According to an exchange filing by RIL on Wednesday, the oil-to-telecom conglomerate revealed that it has offloaded 35 million equity shares of Asian Paints through its subsidiary Siddhant Commercials Limited at Rs 2,201 per share. Before the sale, Siddhant Commercials, a subsidiary of Mukesh Ambani's Reliance Industries, owned a 4.9 percent stake in Asian Paints, as of March 2025. After the block deal, Reliance now holds 8.7 million (87 lakh) equity shares in Asian Paints, as per the filing. Largest stakeholders in Asian Paints While RIL's major block deal has altered the overall shareholding pattern in Asian Paints, the Life Insurance Corporation of India (LIC) remains the company's largest shareholder with an 8.29 percent stake, while domestic mutual funds collecting own a 5.67 percent equity in the firm. As per a report by The Mint, ICICI Prudential Mutual Fund and SBI Mutual Fund own a 1.24 percent and 1.51 percent, stake in Asian Paints, while over 1.17 crore small investors hold 11.84 per cent equity, each holding valued as less than Rs 2 lakh. Notably, the buyers who were part of RIL's block deal remain undisclosed as of yet. Meanwhile, the shares of Reliance Industries closed at Rs 1,439.60 apiece on the BSE , while Asian Paints ended the day at Rs 2,218.05.
&w=3840&q=100)
Business Standard
43 minutes ago
- Business Standard
F-1 to EB-5 visa: How rich Indian students in US seek easier green card
An increasing number of Indian families are opting for the EB-5 investor visa route to secure permanent residency in the United States, as US President Donald Trump tightens controls on student and temporary work visas. The EB-5 visa programme grants Green Cards to foreign nationals who invest 800,000 (approximately Rs 7 crore) in a qualifying US business project. That investment must generate or preserve at least 10 jobs for US workers. Record surge in Indian EB-5 filings "In the first four months of FY2025 alone, Indian applicants filed over 1,200 I-526E petitions across reserved visa categories — more than any prior full year on record," Nicholas Mastroianni III, president and CMO of United States Immigration Fund (USIF), which operates EB-5 regional centres in the US, told Business Standard. According to data obtained through the Freedom of Information Act (FOIA) and published by the American Immigrant Investor Alliance (AIIA) in February 2025, total EB-5 petitions from Indian nationals since October 2022 have exceeded 1,790. Year-wise Indian EB-5 petition filings: FY2020: Around 290 FY2021: Between 80 and 100 (impacted by Covid-19) FY2022: Over 1,100 (post-Reform and Integrity Act revival) FY2023: Around 650 to 700 FY2024: Around 600 to 700 b(October 2024 to January 2025): Over 1,200 "Projections suggest India may cross 2,000 petitions by the end of FY2025 if current momentum continues," Mastroianni added. Who is applying, and why? According to CanAm Enterprises, which manages EB-5 projects, there is a growing number of Indian parents filing petitions while their children are still pursuing undergraduate degrees in the US. Earlier, most applicants were professionals on H-1B visas or parents applying after their child's graduation. Piyush Gupta, vice president for India and the Middle East at CanAm, told Business Standard, "There's a shift. More families are filing in the first or second year of the student's undergraduate programme." Factors contributing to the urgency include: • Risk of visa retrogression in reserved categories like rural and high-unemployment areas • Fears over the proposed 5 million "Trump Gold Card" visa • Stricter enforcement of F-1 student visa conditions • Growing use of social media checks in visa adjudication A hedge against visa uncertainty "Indian parents are increasingly viewing EB-5 as a strategic insurance policy against the uncertainties of H-1B lotteries and student visa limitations," said Varun Singh, managing director at XIPHIAS Immigration. Gupta noted, "There is increasing scrutiny and unpredictability around temporary visa statuses. Parents are unwilling to let their children face decades of visa and work restrictions. EB-5 offers a more direct and secure alternative." "The concurrent filing option is also a major pull," he said. It allows eligible applicants already in the US to file their EB-5 petition and a Green Card application simultaneously, enabling them to work and travel while the case is pending. Mastroianni added, "It's not just about faster Green Cards. It's about independence from lotteries, employers and annual renewals. EB-5 puts families in control." The Trump Gold Card effect The Trump administration's plan to introduce a 5 million investor visa has further pushed Indian applicants to file under the current EB-5 terms. But would the EB-5 still be viable if replaced? "Policy proposals come and go. EB-5 has statutory backing and any replacement would face legal scrutiny," Singh said. "Still, a rise in costs or tighter rules could spark a short-term rush to lock in today's benefits." Gupta pointed to the programme's grandfathering provision, which guarantees that petitions filed before September 30, 2026, will be processed under current rules. He added, "Even if policies change, those who file on time will be shielded. This provides long-term stability." Protective measures in place To address concerns about the security of funds, most regional centres use protected escrow accounts. These accounts hold the investment until USCIS confirms receipt of the petition. "If the petition isn't properly filed, the funds are refunded. These systems offer confidence and legal safeguards for investors," Gupta explained. Why Indian families are acting now Recent developments over the past year have shaped investor sentiment: • In May 2025, the US Embassy warned that minor academic violations could lead to immediate F-1 visa cancellation • SEVIS terminations are increasing due to delays in reporting post-graduation work permits • Visa renewal procedures now involve social media checks, making them less predictable According to Mastroianni, families are not waiting for problems to arise. "They're acting before Optional Practical Training ends or visa rules change." Advantages of the EB-5 visa for Indian students and families Mastroianni listed the main draws: • No employer sponsorship or lottery dependence • Concurrent filing allows students in the US to apply for Green Cards and get work/travel rights quickly • Structured financing solutions help families comply with the RBI's 250,000 Liberalised Remittance Scheme cap Drawbacks and risks Singh cautioned that the EB-5 programme carries risks. "The 800,000 must be invested 'at-risk' for years. There are no guaranteed returns. Projects must meet USCIS job creation and compliance standards. And timelines can vary," he said. Gupta elaborated on investment types: Debt-based investments: These offer more predictable, modest returns (typically 0.25% to 0.5% annually) and clearer exit timelines (usually 4–5 years). Equity-based investments: These carry higher return potential but are riskier, with no guaranteed return or fixed timeline "Most seasoned investors choose debt models because of their predictability and seniority in repayment," he said. Legal challenges around "source of funds" and job creation requirements also add to the complexity. Alternatives to EB-5 Singh noted that while EB-5 remains the only direct investment route to a Green Card, there are workarounds. "The E-2 visa is a common substitute, but India doesn't have a treaty with the US. Some families use Grenadian or Turkish citizenship to qualify. Others look at EB-1C or EB-1A categories, though these are harder to qualify for." He said, "No other route offers EB-5's mix of clarity and control. If changes come, those who filed early will benefit most." Mastroianni added, "Why spend a decade waiting in line when you can secure permanent residency with confidence today? EB-5 isn't just a visa. It's a well-defined legal route for Indian families to settle in the US."
&w=3840&q=100)
Business Standard
43 minutes ago
- Business Standard
Investors' wealth erodes by Rs 5.98 trillion as markets tumble
Investors' wealth eroded by Rs 5.98 trillion on Thursday, tracking weak trends in equities where the BSE Sensex tumbled 1 per cent. Benchmark indices Sensex and Nifty declined 1 per cent in tandem with weak global market trends amid growing tensions in the Middle East. The 30-share BSE Sensex dropped 823.16 points or 1 per cent to settle at 81,691.98. During the day, it plunged 991.98 points or 1.20 per cent to 81,523.16. The market capitalisation of BSE-listed firms dropped by Rs 5,98,759.27 crore to Rs 4,49,58,383.92 crore ($5.26 trillion). "The selloff was triggered by weak global cues, volatility from the weekly F&O expiry, and renewed concerns over global trade and geopolitical tensions. Investors reacted to feeble global cues as markets assessed the uncertain outcome of US-China trade negotiations and rising tensions in the Middle East, which pushed oil prices higher and weighed on risk appetite. "The weekly expiry of derivatives contracts added to intraday volatility and profit-booking, amplifying the downward move," Satish Chandra Aluri, Analyst at Lemonn Markets Desk, said. From the Sensex firms, Tata Motors, Titan, Eternal, Power Grid, Tata Steel, Larsen & Toubro, Mahindra & Mahindra and Hindustan Unilever were among the biggest laggards. Bajaj Finserv, Asian Paints and Tech Mahindra were the gainers. Among sectoral indices, power tumbled 2.19 per cent, utilities (2.18 per cent), oil & gas (2.10 per cent), realty (2.07 per cent), consumer durables (2.02 per cent), industrials (1.98 per cent), auto (1.71 per cent), consumer discretionary (1.67 per cent) and metal (1.63 per cent). As many as 2,729 stocks declined while 1,282 advanced and 140 remained unchanged on the BSE. The BSE midcap gauge tanked 1.52 per cent and smallcap index dropped 1.38 per cent.
